Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Dennis M. Simmons"'
Autor:
S. Lindsey Davis, Sarah J. Hartman, Stacey M. Bagby, Marina Schlaepfer, Betelehem W. Yacob, Tonia Tse, Dennis M. Simmons, Jennifer R. Diamond, Christopher H. Lieu, Alexis D. Leal, Elaine B. Cadogan, Gareth D. Hughes, Stephen T. Durant, Wells A. Messersmith, Todd M. Pitts
Publikováno v:
BMC Cancer, Vol 22, Iss 1, Pp 1-13 (2022)
Abstract Background AZD0156 is an oral inhibitor of ATM, a serine threonine kinase that plays a key role in DNA damage response (DDR) associated with double-strand breaks. Topoisomerase-I inhibitor irinotecan is used clinically to treat colorectal ca
Externí odkaz:
https://doaj.org/article/800be23a70e04aa88362454d6b8fc5c7
Autor:
Sarah J. Hartman, Stacey M. Bagby, Betelehem W. Yacob, Dennis M. Simmons, Morgan MacBeth, Christopher H. Lieu, S. Lindsey Davis, Alexis D. Leal, John J. Tentler, Jennifer R. Diamond, S. Gail Eckhardt, Wells A. Messersmith, Todd M. Pitts
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer with high incidences of p53 mutations. AZD1775 (adavosertib, previously MK-1775) is a small molecule WEE1 inhibitor that abrogates the G2M checkpoint and can potentially synergize with
Externí odkaz:
https://doaj.org/article/3fd57b698eda4a68a4b0e9a0920a5bdc
Autor:
Todd M. Pitts, Dennis M. Simmons, Stacey M. Bagby, Sarah J. Hartman, Betelehem W. Yacob, Brian Gittleman, John J. Tentler, Diana Cittelly, D. Ryan Ormond, Wells A. Messersmith, S. Gail Eckhardt, Jennifer R. Diamond
Publikováno v:
Cancers, Vol 12, Iss 3, p 719 (2020)
Triple-negative breast cancer (TNBC) is an aggressive subtype defined by lack of hormone receptor expression and non-amplified HER2. Adavosertib (AZD1775) is a potent, small-molecule, ATP-competitive inhibitor of the Wee1 kinase that potentiates the
Externí odkaz:
https://doaj.org/article/98303b9316db4c7cb0e1e6133ffcdc79
Autor:
S. Gail Eckhardt, Stacey M. Bagby, Sarah J. Hartman, John J. Tentler, Todd M. Pitts, Jennifer R. Diamond, Diana Cittely, Kyrie L. Dailey, Brian Gittleman, Wells A. Messersmith, D. Ryan Ormond, Betelehem W. Yacob, Dennis M. Simmons
Publikováno v:
Cancer Research. 80:P1-19
Background: Triple-negative breast cancer (TNBC) is an aggressive subtype defined by lack of hormone receptor expression and non-amplified HER2. TNBC accounts for approximately 15% of breast cancer cases, however, is associated with an increased risk
Autor:
S. Lindsey Davis, Sarah J. Hartman, Stacey M. Bagby, Marina Schlaepfer, Betelehem W. Yacob, Tonia Tse, Dennis M. Simmons, Jennifer R. Diamond, Christopher H. Lieu, Alexis D. Leal, Elaine B. Cadogan, Gareth D. Hughes, Stephen T. Durant, Wells A. Messersmith, Todd M. Pitts
Publikováno v:
BMC cancer. 22(1)
Background AZD0156 is an oral inhibitor of ATM, a serine threonine kinase that plays a key role in DNA damage response (DDR) associated with double-strand breaks. Topoisomerase-I inhibitor irinotecan is used clinically to treat colorectal cancer (CRC
Autor:
John J. Tentler, Stacey M. Bagby, Sarah J. Hartman, D. Ryan Ormond, Diana M. Cittelly, Betelehem W. Yacob, Jennifer R. Diamond, Dennis M. Simmons, Wells A. Messersmith, S. Gail Eckhardt, Todd M. Pitts, Brian Gittleman
Publikováno v:
Cancers
Volume 12
Issue 3
Cancers, Vol 12, Iss 3, p 719 (2020)
Volume 12
Issue 3
Cancers, Vol 12, Iss 3, p 719 (2020)
Triple-negative breast cancer (TNBC) is an aggressive subtype defined by lack of hormone receptor expression and non-amplified HER2. Adavosertib (AZD1775) is a potent, small-molecule, ATP-competitive inhibitor of the Wee1 kinase that potentiates the
Autor:
Sarah J. Hartman, Stacey M. Bagby, Betelehem W. Yacob, Dennis M. Simmons, Tonia E. Tse, Christopher H. Lieu, S. Lindsey Davis, Alexis D. Leal, Jennifer R. Diamond, Wells A. Messersmith, Todd M. Pitts
Publikováno v:
Cancer Research. 79:1315-1315
Introduction: Pancreatic ductal adenocarcinoma (PDA) is the fourth leading cause of cancer death and has a 5-year survival rate of less than 7%. The poor prognosis associated with PDA is related in part to a lack of screening tests to promote early d
Autor:
Betelehem W. Yacob, Todd M. Pitts, Gareth Hughes, Tonia Tse, Sarah J. Hartman, Elaine Cadogan, Jennifer R. Diamond, Stephen T. Durant, Marina I. Schlaepfer, Wells A. Messersmith, Dennis M. Simmons, S. Lindsey Davis, Stacey M. Bagby, Christopher H. Lieu, Alexis D. Leal
Publikováno v:
Cancer Research. 79:4720-4720
Background: AZD0156 is an oral inhibitor of ATM, a serine threonine kinase that plays a key role in DNA damage response associated with DNA double strand breaks. Topoisomerase-I inhibitors like irinotecan induce single-strand DNA breaks, which are co